Topics

Biocon Biologics Eyes $1bn In Sales As Q2 Revenues Jump 40%

17:54 EDT 28 Oct 2019 | SCRIP

Strong growth in Biocon's biologics segment continued in the second quarter and the vertical has now set a target of...

      

Related Stories

 

Original Article: Biocon Biologics Eyes $1bn In Sales As Q2 Revenues Jump 40%

NEXT ARTICLE

More From BioPortfolio on "Biocon Biologics Eyes $1bn In Sales As Q2 Revenues Jump 40%"

Quick Search

Relevant Topic

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...